Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkAssociation of Amyloid Reduction After Donanemab Treatment with Tau Pathology and Clinical Outcomes

The TRAILBLAZER-ALZ Randomized Clinical Trial

According to the findings of post-hoc analysis for patients who received donanemab treatment, baseline amyloid levels were directly related to the extent of amyloid reduction and inversely related to the likelihood of obtaining total amyloid clearance. In patients with complete amyloid clearance and in brain areas discovered later in the pathologic sequence, the donanemab-induced slowing of tau was more severe. To support the aforementioned findings, data from additional trials would be crucial, particularly information on treatment response according to APOE ε4 status.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form